Condition: Hepatocellular Carcinoma · Sponsor: Myeloid Therapeutics
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.
This description comes directly from the study's public registry record.
Project Manager · +61 2 8569 1400 · Lucy.FrereScott@novotech-cro.com
Clinical Department · +1 617 465 1022 · 303clinical@myeloidtx.com
Always discuss trial participation with your own doctor first.
| St Vincent's Hospital | Sydney, New South Wales, Australia | Recruiting |
| Integrated Clinical Oncology Network (ICON) Pty Ltd | Woolloongabba, Queensland, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Linear Clinical Research | Murdoch, Western Australia, Australia | Recruiting |
| Pusan National Univesity Hospital | Busan, South Korea | Recruiting |
| Cha University Bundang Medical Center | Gyeonggi-do, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Tzu Chi Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06478693